Abselion is thrilled to announce the successful closure of a $6.6 million funding round, which will significantly enhance our mission of simplifying protein quantification to aid scientists in their critical work developing biotherapeutics. This influx of capital will allow us to expand our innovative portfolio of tools designed to provide researchers with rapid access to actionable data while minimizing hands-on time. At the forefront of our product suite is the award-winning Amperia system, which utilizes our proprietary Redox Electrochemical Detection (RED) technology. This cutting-edge system revolutionizes biologics and viral-vector quantification, enabling confident and cost-effective automated, at-line titre measurements in any laboratory setting.
The funding we’ve secured will be instrumental in further refining our Amperia technology and enhancing our customer service offerings, ensuring that researchers have the resources they need to optimize bioprocesses and drive innovation. Abselion’s dynamic team thrives at the intersection of biology, nanotechnology, and data science, fostering a collaborative environment where creativity and passion are encouraged. This financial boost not only supports our current projects but also empowers us to explore new avenues for development that can ultimately redefine how scientists quantify proteins, thereby accelerating the delivery of tomorrow’s biotherapeutics. We are excited about the future and look forward to making significant strides with the support of our investors and dedicated team.
